Literature DB >> 22819364

A prediction model for N2 disease in T1 non-small cell lung cancer.

Yang Zhang1, Yihua Sun, Jiaqing Xiang, Yawei Zhang, Hong Hu, Haiquan Chen.   

Abstract

OBJECTIVE: Controversy remains over the routine use of mediastinoscopy or positron emission tomography in T1 non-small cell lung cancer without lymph node enlargement on computed tomography because the risk of N2 involvement is comparatively low. We aimed to develop a prediction model for N2 disease in cT1N0 non-small cell lung cancer to aid in the decision-making process.
METHODS: We reviewed the records of 530 patients with computed tomography-defined T1N0 non-small cell lung cancer who underwent surgical resection with systematic lymph node dissection. Correlations between N2 involvement and clinicopathologic parameters were assessed using univariate analysis and binary logistic regression analysis. A prediction model was built on the basis of logistic regression analysis and was internally validated using bootstrapping.
RESULTS: The incidence of N2 disease was 16.8%. Four independent predictors were identified in multivariate logistic regression analysis and included in the prediction model: younger age at diagnosis (odds ratio, 0.974; 95% confidence interval, 0.952-0.997), larger tumor size (odds ratio, 2.769; 95% confidence interval, 1.818-4.217), central tumor location (odds ratio, 3.204; 95% confidence interval, 1.512-6.790), and invasive adenocarcinoma histology (odds ratio, 3.537; 95% confidence interval, 1.740-7.191). This model shows good calibration (Hosmer-Lemeshow test: P = .784), reasonable discrimination (area under the receiver operating characteristic curve, 0.726; 95% confidence interval, 0.669-0.784), and minimal overfitting demonstrated by bootstrapping.
CONCLUSIONS: We developed a 4-predictor model that can estimate the probability of N2 disease in computed tomography-defined T1N0 non-small cell lung cancer. This prediction model can help to determine the cost-effective use of mediastinal staging procedures.
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22819364     DOI: 10.1016/j.jtcvs.2012.06.050

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  26 in total

1.  Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China.

Authors:  Bing Chen; Wenjie Xia; Zhongqiu Wang; Heng Zhao; Xiaofei Li; Lunxu Liu; Yang Liu; Jian Hu; Xiangning Fu; Yin Li; Yijun Xu; Deruo Liu; Haiying Yang; Lin Xu; Feng Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-19       Impact factor: 4.553

2.  Lung cancer screening in China: early-stage lung cancer and minimally invasive surgery 3.0.

Authors:  Difan Zheng; Haiquan Chen
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  External validation of a prediction model for pathologic N2 among patients with a negative mediastinum by positron emission tomography.

Authors:  Farhood Farjah; Leah M Backhus; Thomas K Varghese; James P Manning; Aaron M Cheng; Michael S Mulligan; Douglas E Wood
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

4.  Prediction Model for Nodal Disease Among Patients With Non-Small Cell Lung Cancer.

Authors:  Francys C Verdial; David K Madtes; Billanna Hwang; Michael S Mulligan; Katherine Odem-Davis; Rachel Waworuntu; Douglas E Wood; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2019-01-30       Impact factor: 4.330

5.  Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer.

Authors:  Feichao Bao; Ping Yuan; Xiaoshuai Yuan; Xiayi Lv; Zhitian Wang; Jian Hu
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

6.  Statistical modelling for thoracic surgery using a nomogram based on logistic regression.

Authors:  Run-Zhong Liu; Ze-Rui Zhao; Calvin S H Ng
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

7.  A Prediction Model to Help with the Assessment of Adenopathy in Lung Cancer: HAL.

Authors:  Oisin J O'Connell; Francisco A Almeida; Michael J Simoff; Lonny Yarmus; Ray Lazarus; Benjamin Young; Yu Chen; Roy Semaan; Timothy M Saettele; Joseph Cicenia; Harmeet Bedi; Corrine Kliment; Liang Li; Sonali Sethi; Javier Diaz-Mendoza; David Feller-Kopman; Juhee Song; Thomas Gildea; Hans Lee; Horiana B Grosu; Michael Machuzak; Macarena Rodriguez-Vial; George A Eapen; Carlos A Jimenez; Roberto F Casal; David E Ost
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

8.  Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis.

Authors:  Tomohiro Haruki; Makoto Wakahara; Yuki Matsuoka; Ken Miwa; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-05-23       Impact factor: 1.520

9.  Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients.

Authors:  Andrea Bille; Kaitlin M Woo; Usman Ahmad; Nabil P Rizk; David R Jones
Journal:  Eur J Cardiothorac Surg       Date:  2017-04-01       Impact factor: 4.191

10.  CT-based radiomics signature for the stratification of N2 disease risk in clinical stage I lung adenocarcinoma.

Authors:  Minglei Yang; Yunlang She; Jiajun Deng; Tingting Wang; Yijiu Ren; Hang Su; Junqi Wu; Xiwen Sun; Gening Jiang; Ke Fei; Lei Zhang; Dong Xie; Chang Chen
Journal:  Transl Lung Cancer Res       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.